NCT07484269Recruiting
PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan
Understanding Drug Utilisation, Treatment Patterns, Clinical Outcomes, and Profile of the Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan for the Treatment of Metastatic Prostate Cancer: a Multicountry, AI-powered Registry (PULSE)
Source: ClinicalTrials.gov · Last updated 30 Oct 2026
Brief summary (registry, in English)
The primary objective of the study is to describe real-world drug utilisation of lutetium (177Lu) vipivotide tetraxetan among patients with metastatic prostate cancer
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 753 (estimated)
- First submitted
- 16 Mar 2026
- Start date
- 30 Sept 2026
- Primary completion date
- 31 Jul 2031
- Lead sponsor
- Novartis Pharmaceuticals
- Diseases
- Prostate cancer, Childhood cancers
- NCT number
- NCT07484269
What you commit to
- Study type: Observational
- Planned participants: 753
- From 30 Sept 2026 to the primary completion date, 31 Jul 2031
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- Age ≥ 18 years at index date
- Diagnosis of mPC
- PSMA positive
- Received at least one dose of lutetium (177Lu) vipivotide tetraxetan on or after mPC diagnosis date
- Exclusion criterion:
- Current or prior participation in an investigational study within the 30-day period immediately prior to and including the index date, or within five half-lives of the investigational product (whichever is longer)
Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Novartis Investigative Site Coordinator of this site? Confirm its status | Basel | Switzerland | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.